Enoximone

DB04880ApprovedInvestigationalWithdrawnSmall molecule

Enoximone is a selective phosphodiesterase inhibitor indicated in the short term treatment of congestive heart failure. Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.

Mechanism: Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.
Curator reviewed
Primary indication: For the treatment of congestive heart failure.Curator reviewed · 2 structured indications
Formula / weight: C₁₂H₁₂N₂O₂S · 248.301 g/mol (avg)
Code names: MDL-17043

Resolves to

Compound

UNIIC7Z4ITI7L7CAS77671-31-9ChEMBLCHEMBL249856ChEBI135010PubChem53708KEGGD04004

Clinical / RWD

RxNorm49626ATCC01CE03PharmGKBPA164768794

Structure

InChIKeyZJKNESGOIKRXQY-UHFFFAOYSA-NSMILESCSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1

Targets

Q14432PDE3A

What you can answer from here — as of October 01, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

7ContraindicationsEach with its own population and attribute set

4Marketed productsAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 13 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enoximone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In